ArticleKidney medicine2026

First-line and Second-line Therapy of Zuberitamab in Idiopathic Membranous Nephropathy: A Single-center Retrospective Study.

Linna Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.